

CITATION REPORT

List of articles citing

Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks

DOI: 10.1093/cid/civ1001

Clinical Infectious Diseases, 2016, 62, 675-682.

Source: <https://exaly.com/paper-pdf/65400189/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
72	Factors Associated with Hormonal and Intrauterine Contraceptive Use among HIV-Infected Men and Women in Lilongwe, Malawi: A Cross-Sectional Study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2016 , 2016, 5429316	2.4	5
71	Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?. <i>Aids</i> , 2016 , 30, 2571-2576	3.5	12
70	Practice Bulletin No. 167: Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2016 , 128, e89-e110	4.9	18
69	Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. <i>Drug Safety</i> , 2016 , 39, 1053-1072	5.1	33
68	Pipeline for contraceptive development. <i>Fertility and Sterility</i> , 2016 , 106, 1295-1302	4.8	12
67	International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. <i>Journal of the International AIDS Society</i> , 2016 , 19, 21487	5.4	15
66	Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1499-1505	3.8	11
65	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 529-536	6.1	20
64	A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities. <i>Contemporary Clinical Trials</i> , 2017 , 52, 27-34	2.3	12
63	Drug interactions between hormonal contraceptives and antiretrovirals. <i>Aids</i> , 2017 , 31, 917-952	3.5	52
62	Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1169-1181	5.5	8
61	HIV and contraception. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017 , 29, 419-426	2.4	4
60	Women in HIV trials: improving adherence and outcomes. <i>Lancet HIV,the</i> , 2017 , 4, e530-e531	7.8	3
59	Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1965-1972	3.5	26
58	Quantifying an Adherence Path-Specific Effect of Antiretroviral Therapy in the Nigeria PEPFAR Program. <i>Journal of the American Statistical Association</i> , 2017 , 112, 1443-1452	2.8	9
57	Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene. <i>Naunyn-Schmiedebergis Archives of Pharmacology</i> , 2017 , 390, 971-976	3.4	
56	Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 377-382	4.2	3

55	Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21396	5.4	15
54	The role of family planning in achieving safe pregnancy for serodiscordant couples: commentary from the United States government's interagency task force on family planning and HIV service integration. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21312	5.4	4
53	Strengthening implant provision and acceptance in South Africa with the Any woman, any place, any time approach: An essential step towards reducing unintended pregnancies. <i>South African Medical Journal</i> , 2017 , 107, 939-944	1.5	14
52	A systematic review of contraceptive continuation among women living with HIV. <i>Contraception</i> , 2018 , 98, 8-24	2.5	2
51	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1004-1012	5.1	12
50	Discordance between self-reported contraceptive use and detection of exogenous hormones among Malawian women enrolling in a randomized clinical trial. <i>Contraception</i> , 2018 , 97, 354-356	2.5	3
49	Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1084, 106-112	3.2	7
48	Current and future contraceptive options for women living with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1-12	4	7
47	Factors associated with desired fertility among HIV-positive women and men attending two urban clinics in Lilongwe, Malawi. <i>PLoS ONE</i> , 2018 , 13, e0198798	3.7	13
46	Antiretroviral implants for treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 374-380	4.2	35
45	Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors. 2018 , 297-356		1
44	Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2018 , 32, e4367	1.7	
43	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7
42	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3003-3010	5.1	5
41	CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2019 , 12, 657-666	4.9	5
40	Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya. <i>Contraception</i> , 2019 , 100, 288-295	2.5	2
39	Drug interactions: not just for orally administered drugs. <i>Lancet HIV,the</i> , 2019 , 6, e563-e564	7.8	
38	Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. <i>Lancet HIV,the</i> , 2019 , 6, e601-e612	7.8	7

37	The Effect of Efavirenz on Estradiol Metabolism in Transgender Women. <i>Transgender Health</i> , 2019 , 4, 197-199	4	3
36	The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2019 , 19, 368	4	6
35	Highlights of the Conference on Retroviruses and Opportunistic Infections, 4 th March 2019, Seattle, WA, USA. <i>Journal of Virus Eradication</i> , 2019 , 5, 125-131	2.8	2
34	A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. <i>Aids</i> , 2019 , 33, 1995-2004	3.5	5
33	Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1129-1143	3.8	10
32	Long-Acting HIV Drugs for Treatment and Prevention. <i>Annual Review of Medicine</i> , 2019 , 70, 137-150	17.4	62
31	The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial. <i>Contraception</i> , 2019 , 99, 87-93	2.5	5
30	Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. <i>Clinical Infectious Diseases</i> , 2020 , 71, 517-524	11.6	4
29	Nexplanon failure in a woman with HIV infection in rural Ghana: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 2369-2372	0.7	2
28	Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 182-188	3.1	2
27	Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial. <i>Contraception: X</i> , 2020 , 2, 100027	1.9	0
26	Interactions between Hormonal Contraception and Anti-Retroviral Therapy: An Updated Review. <i>Current Obstetrics and Gynecology Reports</i> , 2020 , 9, 98-104	0.6	2
25	Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 45-53	1.9	3
24	Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. <i>Contraception</i> , 2020 , 102, 174-179	2.5	4
23	The challenge of HIV treatment in an era of polypharmacy. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25449	5.4	40
22	Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 48-58	4.5	5
21	Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 208-216	3.1	1
20	Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 835-853	6.2	15

19	Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy. <i>Polymers</i> , 2021 , 13,	4.5	2
18	In Vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021 , 22, 898-906	2.7	
17	A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1057-1065	6.1	3
16	Pregnancies among women living with HIV using contraceptives and antiretroviral therapy in western Kenya: a retrospective, cohort study. <i>BMC Medicine</i> , 2021 , 19, 178	11.4	2
15	Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	4
14	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. <i>Lancet HIV</i> , 2020 , 7, e401-e409	7.8	16
13	Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, e47-e51	3.1	11
12	Potential risk of drug-drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV. <i>Drugs in Context</i> , 2020 , 9,	5.2	1
11	High-Risk Pregnancy: Management Options. 2018 ,		1
10	Contraceptive implant failures among women using antiretroviral therapy in western Kenya: a retrospective cohort study. <i>Gates Open Research</i> , 2019 , 3, 1482	2.4	1
9	Highlights of the Conference on Retroviruses and Opportunistic Infections, 4-9 March 2019, Seattle, WA, USA. <i>Journal of Virus Eradication</i> , 2019 , 5, 125-131	2.8	
8	CROI 2019: advances in antiretroviral therapy. <i>Topics in Antiviral Medicine</i> , 2019 , 27, 50-68	3.2	12
7	Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorate the Effect of Combined Oral Contraceptive- (COC-) Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats.. <i>International Journal of Reproductive Medicine</i> , 2021 , 2021, 9693171	2.3	1
6	Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin. <i>Clinical Infectious Diseases</i> ,	11.6	0
5	Exploring Challenges Faced by Nurses on Provision of Hormonal Contraceptives to Women on Antiretroviral Therapy in Selected Healthcare Facilities in Lilongwe District, Malawi. Volume 12, 147-157		
4	Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis. 2022 , 25,		0
3	Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.		0
2	Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modelling study.		0

- 1 Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DouBLNG pharmacokinetic study. **2023**, 109975

○